Single Cell Multiomics Market Report 2026

The single cell multiomics market size has grown exponentially in recent years. It will grow from $4.85 billion in 2025 to $5.92 billion in 2026 at a compound annual growth rate (CAGR) of 22.1%. The growth in the historic period can be attributed to advancements in single-cell sequencing technologies, expansion of cancer research initiatives, rising investments in life sciences research, increased availability of high-throughput analysis tools, growing academic research funding.

The single cell multiomics market size is expected to see exponential growth in the next few years. It will grow to $13 billion in 2030 at a compound annual growth rate (CAGR) of 21.7%. The growth in the forecast period can be attributed to rising demand for precision medicine applications, increasing adoption in clinical research workflows, expansion of multiomics data integration platforms, growing pharmaceutical research investments, continuous improvements in analytical sensitivity. Major trends in the forecast period include increasing adoption of integrated multiomics platforms, rising demand for high-resolution single-cell analysis, growing use of AI-driven data interpretation tools, expansion of multi-modal cellular profiling techniques, enhanced focus on cellular heterogeneity insights.

The growing demand for precision medicine is anticipated to drive the expansion of the single-cell multiomics market in the coming years. Precision medicine refers to a healthcare approach that customizes treatment and medical strategies based on the individual characteristics of each patient. The rise of precision medicine is supported by advancements in genomic research, improved data analysis capabilities, and an increased awareness of the benefits of personalized healthcare. Single-cell multiomics offers detailed insights into cellular heterogeneity and molecular mechanisms, facilitating the development of highly personalized treatments tailored to the unique cellular profiles of individual patients. For example, in May 2025, according to the Personalized Medicine Coalition (PMC), a U.S.-based professional organization, the U.S. Food and Drug Administration (FDA) approved 18 new personalized medicines in 2023, accounting for approximately 38% of all newly approved therapeutic molecular entities. Consequently, the rising demand for precision medicine is fueling the growth of the single-cell multiomics market.

Key companies in the single-cell multiomics market are creating single-cell multiomics tests to improve the accuracy and resolution of cellular analysis. These tests allow researchers to gain a deeper understanding of complex biological processes, detect rare cell populations, and advance precision medicine approaches by integrating comprehensive molecular data from individual cells. For instance, in June 2024, Mission Bio, a U.S.-based biotechnology firm, introduced the Tapestri Single-cell Multiple Myeloma Multiomics Solution, which enables extensive profiling of multiple myeloma at single-cell resolution. This solution helps translational researchers and drug developers dissect the molecular and cellular landscape during myeloid progression, investigate therapy resistance, and identify factors driving disease evolution from early stages such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

In July 2024, Illumina, a US-based provider of DNA sequencing, array-based technologies, and genomic informatics solutions, acquired Fluent BioSciences for an undisclosed sum. Through this acquisition, Illumina aimed to strengthen its single-cell and multiomics capabilities, allowing researchers to conduct high-throughput, scalable single-cell analysis with improved accessibility and reduced complexity. Fluent BioSciences is a US-based company developing innovative single-cell technologies, particularly its PipSeq™ V assay, which simplifies single-cell analysis by removing the need for complex instrumentation and microfluidic consumables, thereby broadening its applicability across more laboratories.

Major companies operating in the single cell multiomics market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Illumina Inc., BioRad Laboratories Inc., QIAGEN N.V., BioTechne Corporation, Miltenyi Biotec BV & Co KG, BGI Genomics Co Ltd, 10x Genomics Inc., Molecular Devices LLC, NanoString Technologies Inc., Standard BioTools Inc., Akoya Biosciences Inc., Takara Bio Inc., Synthego Corporation, Mission Bio Inc., DeepCell Inc., RareCyte Inc., Parse Biosciences Inc., Dolomite Bio Ltd, Stilla Technologies SAS, NanoCellect Biomedical Inc., Epicypher Inc., Scipio Biosciences SAS.

North America was the largest region in the single cell multiomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single cell multiomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single cell multiomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the single cell multiomics market by increasing costs of imported sequencing instruments, microfluidics devices, reagents, software platforms, and analytical hardware. Research institutions and biotech companies in North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces higher costs for advanced analytical systems. These tariffs are increasing research budgets and extending procurement cycles. However, they are also encouraging regional manufacturing of laboratory instruments, localized reagent production, and domestic innovation in integrated multiomics technologies.

The single cell multiomics market research report is one of a series of new reports that provides single cell multiomics market statistics, including single cell multiomics industry global market size, regional shares, competitors with a single cell multiomics market share, detailed single cell multiomics market segments, market trends and opportunities, and any further data you may need to thrive in the single cell multiomics industry. This single cell multiomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Single-cell multiomics is a cutting-edge approach that combines multiple types of molecular data, including genomics, transcriptomics, proteomics, and metabolomics, at the level of individual cells. This technique offers a detailed understanding of cellular heterogeneity and function, allowing for more accurate insights into complex biological processes and disease mechanisms.

The primary categories in the single-cell multiomics market include single-cell genomics, single-cell proteomics, single-cell transcriptomics, and single-cell metabolomics. Single-cell genomics involves the study and analysis of the entire genetic material (DNA) within a single cell. Techniques in this area include single-cell isolation and dispensing, as well as single-cell analysis, with applications spanning oncology, cell biology, neurology, immunology, and stem cell research. The end users include academic institutions, contract research organizations, and pharmaceutical and biotechnology companies.

The single cell multiomics market consists of revenues earned by entities by providing services such as single-cell RNA sequencing, cellular imaging, and integrated multiomics solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The single cell multiomics market also includes sales of single cell isolation instruments, library preparation kits, and proteomics assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.